Genmab — Oktober 2018
-
going up
-
har i set, at Caroline har fået konstateret RA?
-
du har helt ret - men GEN havde tilsyneladende ikke taget ved lære af post As
-
ASH blamagen - det markedet så på CMD var en udvidelse af cash burn, mens der ikke blev peget på nogen indtægtskilder
-
så de inspirerede ikke ligefrem tillid til deres equity story
-
cash magically dissapears?
-
from Celgene: POMALYST/IMNOVID net sales increased by 23% year-over-year. In the US, POMALYST net sales grew 34% year-over-year, driven by the continued adoption of the triplet regimen of POMALYST, daratumumab and dexamethasone for relapsed refractory myeloma
-
hahaha, hvor er det fantastisk! Han er en ven af folket
-
kan han ikke også ringe til min netto, og sige at de skal få Løgismoses boller i karry tilbage? Og prisen skal ned?
-
Celgene transcript (revlimid. car t) https://www.fool.com/earnings/call-transcripts/2018/10/25/celgene-corp-celg-q3-2018-earnings-conference-call.aspx
-
isn't the list price for dara the same across the world?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind